Maxcyte (MXCT) Operating Margin (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Margin data on file, last reported at 137.41% in Q1 2026.

• On a quarterly basis, Operating Margin fell 1908.0% year-over-year to 137.41% in Q1 2026; TTM through Mar 2026 was 303.87%, a 13068.0% decrease from a year earlier, with the FY2025 full-year figure at 247.64%, down 1717.0% from the prior year.
• Operating Margin for Q1 2026 stood at 137.41%, down from 235.4% in the prior quarter.
• Over the last five years, Operating Margin for MXCT reached as high as 235.4% in Q4 2025 and fell as low as 335.71% in Q3 2023.
• Historically, Operating Margin has averaged 135.5% across 5 years, with a median of 144.56% in 2023.
• Across the five-year window, Operating Margin plunged 26324 bps in 2023 and surged 44846 bps in 2025, its largest moves.
• Year by year, Operating Margin stood at 87.04% in 2022, then surged by 65 bps to 30.5% in 2023, then tumbled by 599 bps to 213.06% in 2024, then jumped by 210 bps to 235.4% in 2025, then tumbled by 158 bps to 137.41% in 2026.
• Per Business Quant data, the three most recent Operating Margin figures were 137.41% in Q1 2026, 235.4% in Q4 2025, and 207.19% in Q3 2025.